Literature DB >> 15760766

Gene dosage and pathogenesis of Parkinson's disease.

Jason L Eriksen1, Serge Przedborski, Leonard Petrucelli.   

Abstract

Four recent papers related specifically to the familial form of Parkinson's disease reinforce the idea that endogenous levels of alpha-synuclein can strongly influence disease phenotype. Two recent publications of alpha-synuclein-duplication mutations show that the severity of familial Parkinsonian phenotype is dependent upon SNCA gene dosage and corresponding protein levels. Familial point mutations in SNCA were found to impair the efficient lysosomal degradation of alpha-synuclein, potentially resulting in elevated levels of alpha-synuclein. Conversely, the complete knockout of SNCA has little effect on transgenic mice. It is now clear that the regulation of alpha-synuclein levels has potential significance in the pathogenesis and treatment of sporadic PD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15760766     DOI: 10.1016/j.molmed.2005.01.001

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  31 in total

Review 1.  Synaptic vesicle exocytosis.

Authors:  Thomas C Südhof; Josep Rizo
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-12-01       Impact factor: 10.005

2.  Increased expression of α-synuclein by SNCA duplication is associated with resistance to toxic stimuli.

Authors:  Han-Joon Kim; Beom S Jeon; Min-Yung Yoon; Sung-Sup Park; Kwang-Woo Lee
Journal:  J Mol Neurosci       Date:  2012-03-06       Impact factor: 3.444

3.  Decreased expression of lysosomal alpha-galactosiase A gene in sporadic Parkinson's disease.

Authors:  Guanghua Wu; Jian Huang; Xungang Feng; Aimei Zhang; Jifeng Li; Shuchao Pang; Kejin Gu; Haixin Dong; Junping Zhang; Huijie Gao; Bo Yan
Journal:  Neurochem Res       Date:  2011-06-05       Impact factor: 3.996

Review 4.  Diagnosis and treatment of Parkinson disease: molecules to medicine.

Authors:  Joseph M Savitt; Valina L Dawson; Ted M Dawson
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

5.  Upregulation of a small vault RNA (svtRNA2-1a) is an early event in Parkinson disease and induces neuronal dysfunction.

Authors:  Elena Miñones-Moyano; Marc R Friedländer; Joan Pallares; Birgit Kagerbauer; Sílvia Porta; Georgia Escaramís; Isidre Ferrer; Xavier Estivill; Eulàlia Martí
Journal:  RNA Biol       Date:  2013-05-01       Impact factor: 4.652

6.  Identification of a highly neurotoxic α-synuclein species inducing mitochondrial damage and mitophagy in Parkinson's disease.

Authors:  Diego Grassi; Shannon Howard; Minghai Zhou; Natalia Diaz-Perez; Nicolai T Urban; Debbie Guerrero-Given; Naomi Kamasawa; Laura A Volpicelli-Daley; Philip LoGrasso; Corinne Ida Lasmézas
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-27       Impact factor: 11.205

7.  CAG repeat lengths > or =335 attenuate the phenotype in the R6/2 Huntington's disease transgenic mouse.

Authors:  I Dragatsis; D Goldowitz; N Del Mar; Y P Deng; C A Meade; Li Liu; Z Sun; P Dietrich; J Yue; A Reiner
Journal:  Neurobiol Dis       Date:  2008-11-06       Impact factor: 5.996

8.  Whole genome association studies of neuropsychiatric disease: An emerging era of collaborative genetic discovery.

Authors:  Margaret A Keller; Katrina Gwinn; Josefina Nash; Jonathan Horsford; Ran Zhang; Stephen S Rich; Roderick A Corriveau
Journal:  Neuropsychiatr Dis Treat       Date:  2007       Impact factor: 2.570

9.  The effect of alpha-synuclein knockdown on MPP+ toxicity in models of human neurons.

Authors:  Timothy M Fountaine; Lara Lourenco Venda; Nicholas Warrick; Helen C Christian; Patrik Brundin; Keith M Channon; Richard Wade-Martins
Journal:  Eur J Neurosci       Date:  2008-11-21       Impact factor: 3.386

Review 10.  Contribution of yeast models to neurodegeneration research.

Authors:  Clara Pereira; Cláudia Bessa; Joana Soares; Mariana Leão; Lucília Saraiva
Journal:  J Biomed Biotechnol       Date:  2012-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.